About Us
We are developing Protein-Based Regenerative Medicine for major human disease therapies. Our goal is to develop innovative protein drugs including transcription factor (TF) protein drugs that can treat major human diseases, with the ultimate aim of improving human health and enhancing human longevity.
With a global layout, Qurgen runs its headquarters and R&D center in the United States, and has subsidiaries in Shanghai and Suzhou of China, where the industrial production base is located. It also builds a joint laboratory with the Institutes of Biomedical Sciences, Fudan University, to accelerate clinical transformation of scientific achievements and drive the development of global regenerative medicine and innovative pharmaceutical industry.
Become a global leader in protein regenerative medicine and tumor reversal therapy, and build a China-originated, world-class innovative biopharmaceutical brand.
In December 2025
During April–June of 2025
During June–August of 2024
In February 2024
On December 7, 2022
By May 2019
In September 2012
Qurgen Inc. was established in Michigan, USA.
In December 2015
Qurgen obtained an exclusive, permanent and global intellectual property licensing agreement from Wayne State University.
In September 2016
Qurgen announced the successful completion of its Pre-A round financing of 4 million USD that will be used to accelerate the company’s research and development, with a focus on developing Qurgen’s cell-conversion cancer therapy for a Phase I clinical trial.
By May 2019
Qurgen announced that the Company had successfully completed its Series A financing with 12 million USD that will be mainly used for the FDA IND application and clinical studies of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy.
On December 7, 2022
Qurgen received FDA IND approval (IND #152226) for the Phase I clinical trial of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy for all solid tumors.
In February 2024
Qurgen’s 30,000 sq. ft. GMP protein drug manufacturing facility was completed and commissioned.
During June–August of 2024
Qurgen had successfully manufactured two lots of GMP-manufactured SON-DP anti-cancer drugs that met FDA/CDE protein drug quality standard. Both lots of SON-DP will be used in the US and China Phase I clinical trials.
During April–June of 2025
Qurgen had successfully manufactured two lots of GMP-manufactured SON-DP anti-cancer drugs that met FDA/CDE protein drug quality standard. Both lots of SON-DP will be used in the US and China Phase I clinical trials.
In December 2025
Qurgen completed the annual physical examination of five Cynomolgus monkeys.